Document:

EXHIBIT 10.41

 

August 5, 2011

 

Mr. Mark Cosby

***********

***********

 

Dear Mark,

 

On behalf of CVS Caremark, I am pleased to offer you the position of President of CVS Pharmacy and Executive Vice President of CVS Caremark.  You will be an employee of CVS Pharmacy, Inc. (“CVS”), a subsidiary of CVS Caremark Corporation (“CVS Caremark”), and will report to Larry Merlo, President and Chief Executive Officer of CVS Caremark.  If you accept this offer, we anticipate that your first day of employment will be in late August or early September, 2011; you and CVS will agree upon a specific starting date in the near future.

 

This letter sets forth the basic components of your compensation and the conditions of this offer.  It is not intended to be a comprehensive description of all benefits available to you or to provide all of the details of the plans that govern the administration of benefits, as our benefit offerings change periodically.  As an employee, you will be able to access information about your benefits at any time through our employee portal.  In the meantime, if you have questions about your compensation or benefits, please contact me.

 

Compensation

 

Subject to the conditions of your employment set forth below and the commencement of your employment, you will be eligible for the following:

 

·                  Salary:  Your initial annualized base salary will be $900,000.  Paydays are monthly, in the middle of the month.

 

·                  Annual Cash Incentive:  You will be eligible to participate in the CVS Caremark Management Incentive Plan (“MIP”), our annual cash bonus program designed to reward employees for their role in achieving company success.  Your target award will be 150% of your annual base salary.  The actual award amount will be determined in accordance with the provisions of the MIP, based on measures of CVS Caremark’s performance as well as your individual performance.  Notwithstanding the foregoing, for the 2011 performance year only, the amount of your MIP award will be the target amount (i.e., $1,350,000).

 

·                  Annual Equity Award Program:  You will be eligible to participate in CVS Caremark’s Annual Equity Awards program.  The target value of your 2012 Annual Equity Award will be $1,500,000; the actual award will be based on your individual performance and CVS Caremark’s performance, and the awards will be granted in early April 2012.  Based on your position, 50% of the value of your 2012 equity award will be delivered in stock options and 50% will be delivered in restricted stock units (RSUs).  Please note that your receipt of each annual RSU award will be contingent on your

 

 

                        acceptance of certain restrictive covenants, including non-competition, non-solicitation and confidentiality covenants.  Eligibility, target opportunity levels, vesting schedules and the portion of the award allocated to RSUs and stock options are reviewed and subject to adjustment on an annual basis.  The grant date for the Annual Equity Awards program typically occurs in April of each year.  All equity awards are subject to the 2010 Incentive Compensation Plan of CVS Caremark Corporation as well as the terms of the agreements granting stock options and RSUs.

 

·                  Long Term Incentive Plan:  You will be eligible to participate in the CVS Caremark Long Term Incentive Plan (“LTIP”)  beginning with the 2011-2013 performance cycle.  Your target LTIP award value for the 2011-2013 performance cycle will be $2,000,000 and your target LTIP award value for the 2012-2014 performance cycle will be $1,500,000.  Under the terms of the LTIP, 50% of the actual award is payable in cash and 50% is payable in CVS Caremark common stock, subject to a two-year hold period.  The actual LTIP award amounts will be determined in accordance with the terms of the LTIP.  Eligibility and target award levels are reviewed and subject to adjustment on an annual basis.  If the Company terminates your employment without Cause (as defined below) and you receive severance, then you will be eligible for the LTIP award, determined in accordance with the LTIP and pro-rated based on the length of the performance cycle completed as of the last day of your employment.

 

·                  Sign-on Equity Award:  Contingent upon the commencement of your employment with CVS, you will be granted an award of RSUs and an award of stock options at the time you begin working for the Company.  The value of the RSUs as of the grant date will be $4,500,000, of which one third will vest on the date you begin work, one third will vest on the first anniversary of your start date, and one third will vest on the second anniversary of your start date.  Disposition of the RSUs will be subject to a two-year hold period following each vesting date.  The Black-Scholes value of the stock options as of the grant date will be $1,500,000.  One third of the options will vest on the first anniversary of your start date, one third of the options will vest on the second anniversary of your start date, and one third of the options will vest on the third anniversary of your start date.  These sign-on equity awards will be subject to the 2010 Incentive Compensation Plan of CVS Caremark Corporation as well as the terms of the agreements granting the RSUs and stock options.  If your employment is terminated by the Company without Cause and you receive severance, then, provided that you remain compliant at all times with your obligations under the Non-Competition, Non-Disclosure and Developments Agreement:  (a) the sign-on equity awards will continue to vest during the severance period; (b) any portions of the sign-on equity awards that have not vested as of the last day of the severance period shall accelerate and vest on the last day of the severance period, and (c) you will have one year from the end of the severance period to exercise such options, not to exceed the maximum term of the option.

 

·                  Return on Net Assets Long Term Incentive Plan (“RoNA LTIP”):  You will be eligible to participate in the RoNA LTIP for the July 2010 through December 2011 cycle.  The target value of this award will be $1,000,000 and will be paid in cash.  The actual award amount will be determined in accordance with the terms of the RoNA LTIP, provided that the award will not be prorated based on your service with the Company except as follows:  if the Company terminates your employment without Cause during the performance period and you receive severance, then you will be eligible for a RoNA LTIP award, determined in accordance with the RoNA LTIP and

 

2

 

pro-rated based on the length of the performance period completed as of the last day of your employment.

 

·                  Benefits:  CVS Caremark offers a wide range of benefits to our employees, including medical and dental insurance, a 401(k) plan, an Employee Stock Purchase Plan, and many other benefits as set forth on the enclosed benefits summary.  Your benefits will include an annual financial planning allowance of $15,000 per year and the installation and maintenance of a home security system selected by the Company.  You will also be eligible for our executive relocation benefit plan, including reimbursement for a home-finding trip for a maximum of six nights, temporary living accommodations for up to 90 days, home sale assistance, reimbursement of closing costs on a home purchase, and moving expenses.  Following the commencement of your employment with CVS, for business travel you will be eligible to use the Company jet or for reimbursement for First Class or Business Class seating if the Company jet is not available.  Please note that certain benefits require minimum tenure before you are eligible to participate and that our benefit offerings are subject to change.  If you incur extra costs to continue your health insurance coverage pursuant to COBRA until you become eligible to participate in CVS Caremark’s medical insurance program, you will be eligible to receive reimbursement for your additional costs, up to a maximum of $2,500.00.

 

·                  Deferred Compensation Plan:  You will be eligible to participate in the CVS Caremark Deferred Compensation Plan, which allows you to defer, on a pre-tax basis and with some limitations, up to 100% of your annual cash incentive and up to 85% of your annual base salary, and receive up to a 5% match of eligible compensation after one year of employment.

 

·                  Deferred Stock Compensation Plan: You will be eligible to participate in the CVS Caremark Deferred Stock Compensation Plan, which allows you to defer up to 100% of restricted stock units you receive.

 

·                  Vacation:  You will be eligible to accrue up to four weeks of vacation per calendar year, pro-rated for any partial years.  You will begin accruing vacation as of your first day of employment.  More information about your vacation accrual and usage is set forth in the CVS Caremark vacation policy.

 

·                  Change in Control Agreement: You will be eligible for CVS Caremark’s standard Change in Control Agreement.  As set forth in the Change in Control Agreement, you would be eligible for a severance benefit equal to 1.5 times your base salary and annual target bonus in the event that you were terminated involuntarily after a change in control (as defined in the Change in Control Agreement).

 

·                  Eligibility for Severance Pay.  In the event that your employment is terminated by the Company without Cause, CVS will offer you a separation agreement in a form provided by the Company that will include monthly severance payments in an amount equal to your monthly base salary in effect immediately prior to your separation, a pro rata MIP award for the year of termination (payable when MIP awards are ordinarily paid), as well as the opportunity to continue participating in the Company’s medical, prescription and dental insurance plans (collectively, the “health benefits”) on the same terms available during your employment, for 18 months or the date on which you obtain employment elsewhere, whichever occurs first.  In addition, if your employment is 

 

3

 

                        terminated by the Company without Cause and you receive severance, you will also be eligible for benefits in accordance with the terms described above in the sections of this offer letter labeled “Long Term Incentive Plan,” “Sign-on Equity Award” and “Return on Net Assets Long Term Incentive Plan.”  The separation agreement will also include a general release of claims and other standard provisions.  For purposes of this offer letter, Cause shall mean that the Company, in its sole discretion, has determined that you have: (a) violated the terms of your Non-Competition, Non-Disclosure and Developments Agreement; (b) willfully violated the CVS Caremark Code of Conduct or any of CVS Caremark’s other policies; (c) engaged in dishonest or fraudulent conduct; or (d) willfully engaged in conduct that is detrimental to CVS Caremark’s reputation.  If you resign from your employment with CVS or are terminated with Cause, you will not be eligible for severance pay.

 

Conditions of Offer

 

This offer and your employment are contingent upon the successful results of a drug-screening test as well as a criminal background check.  We will provide instructions for scheduling a drug testing appointment, which must be completed within 48 hours of your receiving this written offer.

 

In addition, as a condition of this offer and your employment with CVS, you are required to sign the Non-Competition, Non-Disclosure and Developments Agreement attached hereto prior to beginning your employment.  Further, you agree that you will not disclose or use, except in the course of your duties for CVS, any Confidential Information (as defined in the Non-Competition, Non-Disclosure and Developments Agreement) that is or has been provided to you by CVS prior to your employment with the Company.

 

CVS prohibits its employees from using or disclosing trade secrets or other confidential information from prior employers in connection with their employment at CVS.  Accordingly, as a further condition of your employment with CVS, you may not use or disclose any confidential information or trade secrets from Macy’s, Inc. (“Macy’s”) or any other former employer.

 

We understand that you have entered into a Noncompetition, Nonsolicitation and Confidential Information Agreement with Macy’s (the “Macy’s Noncompete Agreement”).  As you know, we have shared CVS’s confidential information with you regarding CVS’s aggregate sales revenue for FY 2010 for the categories of Cosmetics, Fragrances and Skin Care.  You have represented to us that, based on the information that we provided you, in the aggregate, CVS does not derive revenue in excess of 50% of Macy’s total revenues for the most recently completed fiscal year from the same categories of merchandise that are offered by Macy’s.  Based on this representation, CVS believes that the Macy’s Noncompete Agreement will not prevent you from accepting this offer or fulfilling your job duties in the position offered.  In recognition thereof, this offer, the commencement of your employment at CVS and your entitlement to any proposed compensation and benefits set forth herein are contingent upon your material representations, and by signing below you hereby represent and warrant, that all information you have communicated to CVS bearing upon the applicability of the Macy’s Noncompete Agreement is accurate and complete.

 

It is essential to CVS that any potential dispute with Macy’s regarding your Macy’s Noncompete Agreement be avoided or resolved promptly and amicably and, as a condition of this offer, you agree to act in good faith and cooperate fully with CVS in the event of such

 

4

 

dispute.  You and CVS acknowledge that it is possible that unanticipated delays may occur in connection with your departure from Macy’s, including but not limited to delays related to the exercise of your Macy’s stock options or sale of Macy’s stock, delays in discussing the matter of your Macy’s Noncompete Agreement with Macy’s, and/or delays arising from a dispute with Macy’s concerning your Macy’s Noncompete Agreement.  Accordingly, CVS expressly reserves the right (a) to delay the commencement of your employment and/or (b) to withdraw this offer in the event that a dispute with Macy’s arises concerning your Macy’s Noncompete Agreement and CVS determines that a resolution of the dispute cannot be reached in a manner or in an amount of time that is satisfactory to the Company.  In making such decision, CVS will act reasonably and in good faith.

 

In the event that CVS withdraws this offer and you do not become an employee of CVS because of a dispute regarding the Macy’s Noncompete Agreement and do not remain an employee of Macy’s or otherwise retain the value of your equity with Macy’s, CVS will pay you the total amount of $3.375 Million, paid in equal monthly installments over the course of eighteen (18) months, provided that no such payments shall be due if any of the representations made by you and upon which CVS has relied in assessing the applicability of the Macy’s Noncompete Agreement to your employment with CVS are inaccurate.  This payment is further conditioned on (a) your execution of a release of claims against the Company in the form provided by the Company and (b) your agreement, subject to any limitations placed on you by the Macy’s Noncompete Agreement, to provide consulting services to CVS during the 18-month payment period at no additional fee.  Further, in the event that a dispute with Macy’s arises after you have started work with CVS and CVS decides to suspend your employment while the issue is resolved, CVS will continue to pay your salary and provide benefits during the period of such suspension, and such time will count as active employment for the purpose of vesting periods associated with your equity awards and incentive payments.  In the event that your employment is terminated by the Company without Cause while you are suspended due to a dispute with Macy’s concerning the Macy’s Noncompete Agreement, CVS will offer you a separation agreement in a form provided by the Company that will offer the benefits described above in the section of this offer letter labeled “Eligibility for Severance Pay.”  In the event that you resign from your employment with CVS or are terminated with Cause while you are suspended due to a dispute with Macy’s concerning the Macy’s Noncompete Agreement, you will not be eligible for severance pay.

 

Also in connection with our discussions regarding this offer you have provided copies of various Nonqualified Stock Option Agreements between you and Macy’s dated March 23, 2007, March 20, 2009, March 19, 2010, and March 25, 2011 (the “Macy’s NQSO’s”), as well as various Performance-Based Restricted Stock Unit Agreements between you and Macy’s dated March 20, 2009, March 19, 2010, and March 25, 2011 (the “Macy’s RSUs”).  You have represented that, apart from these Macy’s NQSO’s, these Macy’s RSUs and the Macy’s Noncompete Agreement, you have no other agreements in your possession between you and Macy’s relating to your current terms, conditions and benefits of employment with Macy’s.  CVS has materially and substantially relied upon your representations in this regard in making this offer.  In recognition thereof, this offer, the commencement of your employment at CVS and your entitlement to any proposed compensation and benefits set forth herein are contingent upon your material representations, and by signing below you hereby represent and warrant, that apart from the Macy’s NQSO’s, the Macy’s RSUs and the Macy’s Noncompete Agreement, you have no other agreements in your possession between you and Macy’s relating to your terms, conditions and benefits of employment with Macy’s,

 

5

 

and that you are not aware of any other agreements between you and Macy’s relating to your terms, conditions and benefits of employment with Macy’s.

 

While we anticipate that you will have a long, successful and rewarding career with CVS Caremark, this offer is for “at will” employment, and either you or CVS Caremark may terminate the employment relationship at any time and for any reason.

 

Please indicate your acceptance of this offer by countersigning this letter and returning the original to me, along with the requested new hire paperwork in this package, including the Non-Competition, Non-Disclosure and Developments Agreement.  Please remember to retain a copy of this letter as well as a copy of the Non-Competition, Non-Disclosure and Developments Agreement.

 

Sincerely,

 

	
/s/   Lisa G. Bisaccia
    	
 
    
	
 
    
	
Lisa   G. Bisaccia
    
	
Senior   Vice President, Chief Human Resources Officer
    
	
CVS   Caremark
    

 

 

Attachments

 

Accepted and agreed to on the 8th day of August, 2011.

 

 

	
/s/   Mark Cosby
    	
 
    
	
Mark   Cosby
    

 

6EXHIBIT 10.42

 

 

CVS CAREMARK CORPORATION

 

Change in Control Agreement for

 

Mark Cosby

 

 

	
CONFIDENTIAL
    	
 
    	
As revised through August 2011
    

 

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    	
 
    
	
1.
    	
Definitions
    	
1
    
	
 
    	
 
    	
 
    
	
2.
    	
Term   of Agreement
    	
4
    
	
 
    	
 
    	
 
    
	
3.
    	
Entitlement   to Severance Benefit
    	
5
    
	
 
    	
 
    	
 
    
	
4.
    	
Confidentiality;   Cooperation with Regard to Litigation; Non-disparagement
    	
7
    
	
 
    	
 
    	
 
    
	
5.
    	
Non-solicitation
    	
8
    
	
 
    	
 
    	
 
    
	
6.
    	
Remedies
    	
8
    
	
 
    	
 
    	
 
    
	
7.
    	
Effect   of Agreement on Other Benefits
    	
9
    
	
 
    	
 
    	
 
    
	
8.
    	
Not   an Employment Agreement
    	
9
    
	
 
    	
 
    	
 
    
	
9.
    	
Resolution   of Disputes
    	
9
    
	
 
    	
 
    	
 
    
	
10.
    	
Assignability;   Binding Nature
    	
9
    
	
 
    	
 
    	
 
    
	
11.
    	
Representation
    	
9
    
	
 
    	
 
    	
 
    
	
12.
    	
Amendment   or Waiver; Section 409A
    	
9
    
	
 
    	
 
    	
 
    
	
13.
    	
Severability
    	
10
    
	
 
    	
 
    	
 
    
	
14.
    	
Survivorship
    	
10
    
	
 
    	
 
    	
 
    
	
15.
    	
Beneficiaries/References
    	
10
    
	
 
    	
 
    	
 
    
	
16.
    	
Governing   Law/Jurisdiction
    	
10
    
	
 
    	
 
    	
 
    
	
17.
    	
Notices
    	
10
    
	
 
    	
 
    	
 
    
	
18.
    	
Headings
    	
11
    
	
 
    	
 
    	
 
    
	
19.
    	
Counterparts
    	
11
    

 

 

This Change in Control Agreement (“Agreement”) is made and entered into as of September 1, 2011 between CVS Pharmacy, Inc. (“CVS”) and Mark Cosby (the “Executive”).

 

WHEREAS, the Board of Directors (the “Board”) of CVS Caremark Corporation (“CVS Caremark” or the “Company”) believes it is necessary and desirable for the Company to be able to rely upon Executive to continue serving in Executive’s position with the Company in the event of a pending or actual change in control of CVS Caremark;

 

WHEREAS, Executive is employed by a Subsidiary of CVS Caremark, and this Agreement shall not alter Executive’s status as an employee at will;

 

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which is mutually acknowledged, CVS and the Executive (individually a “Party” and together the “Parties”) agree as follows:

 

1.                                      Definitions.

 

a.                                      “Base Salary” shall mean Executive’s annual rate of base salary at the time of Executive’s termination of employment or, if greater, as in effect immediately prior to a Change in Control.

 

b.                                      “Cause” shall exist if:

 

i.                                          Executive willfully and materially breaches Sections 4 or 5 of this Agreement;

 

ii.                                       Executive is convicted of a felony involving moral turpitude; or

 

iii.                                    Executive engages in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out Executive’s duties under this Agreement, resulting, in either case, in material harm to the financial condition or reputation of the Company.

 

For purposes of this Agreement, an act or failure to act on Executive’s part shall be considered “willful” if it was done or omitted to be done by Executive not in good faith, and shall not include any act or failure to act resulting from any incapacity of Executive. A termination for Cause shall not take effect absent compliance with the provisions of this paragraph. Executive shall be given written notice by the Company of its intention to terminate Executive’s employment for Cause, such notice (A) to state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination for Cause is based and (B) to be given within 90 days of the Company’s learning of such act or acts or failure or failures to act. Executive shall have 20 days after the date that such written notice has been given to Executive in which to cure such conduct, to extent such cure is possible. If Executive fails to cure such conduct, Executive shall then be entitled to a hearing before the Committee, or an officer or officers designated by the Committee, at which Executive is entitled to appear. Such hearing shall be held within 25 days of such notice to Executive, provided Executive requests such hearing within 10 days of the written notice from the Company of the intention to terminate Executive for Cause. If, within five days following such hearing, Executive is furnished written notice by the Committee confirming that, in its judgment, grounds for Cause on the basis of the original notice exist, Executive shall thereupon be terminated for Cause. Executive’s right to cure in accordance with this provision applies only in the event of a Change in Control as defined in Section 1(c) below and does not alter Executive’s “at will” employment status.

 

1

 

c.                                       A “Change in Control” shall be deemed to have occurred if:

 

(i)                                     any Person (other than (w) the Company, (x) any trustee or other fiduciary holding securities under any employee benefit plan of the Company, (y) any company owned, directly or indirectly, by the stockholders of the Company immediately after the occurrence with respect to which the evaluation is being made in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such occurrence or (z) any surviving or resulting entity from a merger or consolidation referred to in clause (iii)  below that does not constitute a Change of Control under clause (iii) below) becomes the Beneficial Owner (except that a Person shall be deemed to be the Beneficial Owner of all shares that any such Person has the right to acquire pursuant to any agreement or arrangement or upon exercise of conversion rights, warrants or options or otherwise, without regard to the sixty day period referred to in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company or of any subsidiary owning directly or indirectly all or substantially all of the consolidated assets of the Company (a “Significant Subsidiary”), representing 30% or more of the combined voting power of the Company’s or such Significant Subsidiary’s then outstanding securities;

 

(ii)                                  during any period of twelve (12) consecutive months, individuals who at the beginning of such period constitute the Board, and any new director whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the twelve (12) month period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board;

 

(iii)                               the consummation of a merger or consolidation of the Company or any Significant Subsidiary with any other entity, other than a merger or consolidation which would result in the voting securities of the Company or a Significant Subsidiary outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or resulting entity) more than 50% of the combined voting power of the surviving or resulting entity outstanding immediately after such merger or consolidation; or

 

(iv)                              the consummation of a transaction (or series of transactions within a 12 month period) which constitutes the sale or disposition of all or substantially all of the consolidated assets of the Company but in no event assets having a gross fair market value of less than 40% of the total gross fair market value of all of the consolidated assets of the Company (other than such a sale or disposition immediately after which such assets will be owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such sale or disposition).

 

For purposes of this definition:

 

(A)                               The term “Beneficial Owner” shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act (including any successor to such Rule).

 

2

 

(B)                               The term “Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.

 

(C)                               The term “Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including “group” as defined in Section 13(d) thereof.

 

d.                                      “Committee” shall mean the Management Planning and Development Committee of the Board, or the corresponding committee of the board of directors of a successor to CVS Caremark.

 

e.                                       “Company” shall mean, collectively, CVS Caremark and any Subsidiary or affiliate of CVS Caremark.

 

f.                                        “Confidential Information” shall have the meaning set forth in Section 4 below.

 

g.                                       “Constructive Termination Without Cause” shall mean a termination of the Executive’s employment at Executive’s initiative following the occurrence, without the Executive’s written consent, of one or more of the following events (except as a result of a prior termination):

 

i.                                          an assignment of any duties to Executive that is inconsistent with Executive’s status as a member of the senior management of CVS Caremark;

 

ii.                                       a decrease in Executive’s annual base salary or target annual incentive award opportunity;

 

iii.                                    any failure to secure the agreement of any successor to CVS Caremark to fully assume the Company’s obligations under this Agreement; or

 

iv.                                   a relocation of Executive’s principal place of employment more than 35 miles from Executive’s place of employment before such relocation.

 

h.                                      “Disability” shall mean disability as that term is defined in the Company’s Long-Term Disability Plan.

 

i.                                          “Effective Date” shall have the meaning set forth in Section 2 below.

 

j.                                         “Original Term” shall have the meaning set forth in Section 2 below.

 

k.                                      “Renewal Term” shall have the meaning set forth in Section 2 below.

 

l.                                          “Severance Period” shall mean the period of 18 months following the termination of Executive’s employment with the Company.

 

m.                                  “Subsidiary” shall have the meaning set forth in Section 4 below.

 

n.                                      “Term” shall have the meaning set forth in Section 2 below.

 

o.                                      “termination of employment”, “employment is terminated” and other similar words shall mean with respect to Executive

 

3

 

(i)            for any plan or arrangement that is subject to the rules of Section 409A of the Internal Revenue Code (the “Code”) a “Separation from Service” as such term is defined in the Income Tax Regulations under Section 409A (the “409A Regulations”) of the Code as modified by the rules described below:

 

(A)                               except in the case where Executive is on a bona fide leave of absence pursuant to the Company’s policies as provided below, Executive is deemed to have incurred a Separation from Service on a date if the company and Executive reasonably anticipate that the level of services to be performed by Executive after such date would be permanently reduced to 20% or less of the average services rendered by Executive during the immediately preceding 36-month period (or the total period of employment, if less than 36 months), disregarding periods during which Executive was on a bona fide leave of absence;

 

(B)                               if Executive is absent from work due to military leave, sick leave, or other bona fide leave of absence pursuant to the Company’s policies, Executive shall incur a Separation from Service on the first date that the rules of (A), above, are satisfied following the later of (i) the six-month anniversary of the commencement of the leave or (ii) the expiration of Executive’s right, if any, to reemployment under statute, contract or Company policy;

 

(C)                               Executive shall be considered to continue employment and to not have a Separation from Service while on a bona fide leave of absence pursuant to the Company’s policies if the leave does not exceed 6 consecutive months (12) months for a disability leave of absence) or, if longer, so long as the Executive retains a right to reemployment with the Company or an Affiliate under an applicable statute, contract or Company policy.  For this purpose, a “disability leave of absence” is an absence due to any medically determinable physical or mental impairment of Executive that can be expected to result in death or can be expected to last for a continuous period of not less than 6 months, where such impairment causes Executive to be unable to perform the duties of Executive’s job or a substantially similar job;

 

(D)                               for purposes of determining whether another organization is an Affiliate of the Company, common ownership of at least 50% shall be determinative;

 

(E)                                the Company specifically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated party constitutes a Separation from Service with respect to Executive providing services to the seller immediately prior to the transaction and providing services to the buyer after the transaction.  Such determination shall be made in accordance with the requirements of Section 409A of the Code; or

 

(ii)                                  for any plan or arrangement that is not subject to the rules of Section 409A of the Code, the complete cessation of providing service to the Company or any Affiliate as an employee.

 

2.                                      Term of Agreement.

 

The term of this Agreement shall commence on the date of this Agreement (the “Effective Date”) and end on the third anniversary of such date (the “Original Term”).  The Original Term shall be automatically renewed for successive one-year terms (the “Renewal Terms”) unless at least 180

 

4

 

days prior to the expiration of the Original Term or any Renewal Term, either Party notifies the other Party in writing that he/she or it is electing to terminate this Agreement at the expiration of the then current Term. “Term” shall mean the Original Term and all Renewal Terms.  If a Change in Control shall have occurred during the Term, notwithstanding any other provision of this Section 2, the Term shall not expire earlier than two years after such Change in Control.

 

3.                                      Entitlement to Severance Benefit.

 

a.                                      Severance Benefit.  In the event Executive’s employment with the Company is Terminated Without Cause, other than due to death, or Disability, or in the event there is a Constructive Termination Without Cause within two years following a Change in Control, Executive shall be entitled to receive:

 

i.                                          Base Salary through the date of termination of Executive’s employment, which shall be paid in a cash lump sum not later than 15 days following Executive’s termination of employment;

 

ii.                                       An amount equal to 1.5 times Executive’s Base Salary in effect on the date of termination of Executive’s employment (or in the event a reduction in Base Salary is a basis for a Constructive Termination Without Cause, then the Base Salary in effect immediately prior to such reduction), payable in a cash lump sum promptly (but in no event later than 15 days) following Executive’s termination of employment;

 

iii.                                    An amount equal to the sum of (A) the most recently established target annual cash incentive bonus amount, pro rated based on the portion of the performance year that Executive has worked as of the date of Executive’s termination, plus (B) 25% of Base Salary (which represents an amount equal to the cash value of the target annual Performance-Based Restricted Stock unit award for the year in which termination occurs), pro rated based on the portion of the performance year that Executive has worked as of the date of Executive’s termination.  The Base Salary will be determined in accordance with Section 3.a.ii. Such payment of a pro rata annual cash incentive bonus and cash in lieu of Performance-Based Restricted Stock will be payable in a cash lump sum promptly (but in no event later than 15 days) following Executive’s termination of employment;

 

iv.                                   An amount equal to 1.5 times the sum of (A) the most recently established target annual incentive cash bonus amount, plus (B) 25% of Base Salary (determined in accordance with Section 3.a.ii above), payable in a cash lump sum promptly (but in no event later than 15 days) following the Executive’s termination of employment;

 

v.                                      Elimination of all restrictions on any restricted stock or restricted .stock unit awards outstanding at the time of termination of employment (other than awards under the Company’s Partnership Equity Program, which shall be governed by the terms of such awards);

 

vi.                                   Immediate vesting of all outstanding stock options and the right to exercise such stock options for the remainder of the full term of such option (other than awards under the Company’s Partnership Equity Program, which shall be governed by the terms of such awards);

 

vii.                                The balance of any incentive awards earned as of December 31 of the prior year (but not yet paid), which shall be paid in a single lump sum not later than 15 days following Executive’s termination of employment;

 

5

 

viii.                             Settlement of all deferred compensation arrangements in accordance with any then applicable deferred compensation plan or election form;

 

ix.                                   Continued participation in all medical, health and life insurance plans at the same benefit level at which Executive was participating on the date of termination of Executive’s employment until the earlier of:

 

1.              the end of the Severance Period; or

 

2.              the date, or dates, Executive receives equivalent coverage and benefits under the plans and programs of a subsequent employer (such coverage and benefits to be determined on a coverage-by-coverage, or benefit-by-benefit, basis);

 

provided that (1) if Executive is precluded from continuing Executive’s participation in any employee benefit plan or program as provided in this clause (ix) of this Section 3.a, Executive shall receive cash payments equal on an after-tax basis to the cost to Executive of obtaining the benefits provided under the plan or program in which Executive is unable to participate for the period specified in this clause (ix) of this Section 3.a, (2) such cost shall be deemed to be the lowest reasonable cost that would be incurred by Executive in obtaining such benefit on an individual basis, and (3) payment of such amounts shall be made quarterly in advance; and

 

x.                                      other or additional benefits then due or earned in accordance with applicable plans and programs of the Company.

 

b.                                      Change in Control Best Payments Determination.  In the event the Severance Benefits described in Section 3(a) are payable to Executive in connection with a Change in Control and, if paid, could subject Executive to an excise tax under Section 4999 of the Internal Revenue Code (the “Excise Tax”), then notwithstanding the provisions of Section 3(a) the Company shall reduce the Severance Benefits (the “Benefit Reduction”) under Section 3(a) by the amount necessary to result in the Executive not being subject to the Excise Tax if such reduction would result in the Executive’s “Net After-Tax Amount” attributable to the Severance Benefits described in Section 3(a) being greater than it would be if no Benefit Reduction was effected.  For this purpose “Net After-Tax Amount” shall mean the net amount of Severance Benefits Executive is entitled to receive under this Agreement after giving effect to all Federal, state and local taxes which would be applicable to such payments, including, but not limited to, the Excise Tax.  The determination of whether any such Benefit Reduction shall be effected shall be made by a nationally recognized public accounting firm selected by the Company (the “Accounting Firm”) prior to the occurrence of the Change in Control and such determination shall be binding on both Executive and the Company.  In the event it is determined that a Benefit Reduction is required, such reduction of items described in Section 3(a) above shall be done first by reducing cash severance determined in accordance with Section 3(a)(ii), 3(a)(iii) and 3(a)(iv); to the extent a further Benefit Reduction is necessary, then Severance Benefits will be reduced from the amounts determined in accordance with Section 3(a)(v) and 3(a)(vi), all as determined by the Accounting Firm.

 

c.                                       No Mitigation; No Offset.  In the event of any termination of employment under this Section 4, Executive shall be under no obligation to seek other employment, and the amounts due Executive under this Agreement shall not be offset by any remuneration attributable to any subsequent employment that Executive may obtain.

 

d.                                      Nature of Payments.  Any amounts due under this Section 3 are in the nature of severance payments considered to be reasonable by the Company and are not in the nature of a penalty.

 

6

 

e.                                       Exclusivity of Severance Benefit.  Upon termination of Executive’s employment during the Term, Executive shall not be entitled to any severance payments or severance benefits from the Company, or any other payments by the Company, other than the Severance Benefit provided in this Section 3, except as required by law.

 

f.                                        General Release of Claims.  Executive agrees, as a condition of payment of the Severance Benefit provided for in this Section 3, that Executive will execute within 60 days of Executive’s termination of employment a separation agreement, in a form reasonably satisfactory to the Company, that includes a general release of any and all claims arising out of Executive’s employment or termination of employment with the Company, other than claims for (i) enforcement of this Agreement, (ii) enforcement of Executive’s rights under any of the Company’s incentive compensation, equity and/or employee benefit plans and programs to which Executive is entitled under this Agreement, and (iii) any tort for personal injury not arising out of or related to Executive’s employment or termination of employment.

 

g.                                       Subject to the provisions of Section 12(b), all payments to be made pursuant to this Section 3 upon the termination of employment of Executive shall be made or commence, as the case may be, within 75 days after the Executive’s termination of employment provided, however, that if such termination of employment is after October 15 of a year, the payout or first payment, as the case may be, shall be made at the end of such 75 day period.

 

4.                                      Confidentiality; Cooperation with Regard to Litigation; Non-disparagement.

 

a.                                      During the Term and thereafter, Executive shall not, without the prior written consent of the Company, disclose to anyone (except in good faith in the ordinary course of business to a person who will be advised by Executive to keep such information confidential) or make use of any confidential information except in the performance of Executive’s duties hereunder or when required to do so by legal process, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) that requires Executive to divulge, disclose or make accessible such information. In the event that Executive is so ordered, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such order.

 

b.                                      During the Term and thereafter, Executive shall not disclose the existence or contents of this Agreement beyond what is disclosed in the proxy statement or documents filed with the government unless and to the extent such disclosure is required by law, by a governmental agency, or in a document required by law to be filed with a governmental agency or in connection with enforcement of Executive’s rights under this Agreement. In the event that disclosure is so required, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such requirement. This restriction shall not apply to such disclosure by Executive to members of Executive’s immediate family, Executive’s tax, legal or financial advisors, any lender, or tax authorities, or to potential future employers to the extent necessary, each of whom shall be advised not to disclose such information.

 

c.                                       Confidential Information” shall mean all information concerning the business of the Company or any Subsidiary relating to any of their products, product development, trade secrets, customers, suppliers, finances, and business plans and strategies. Excluded from the definition of Confidential Information is information (i) that is or becomes part of the public domain, other than through the breach of this Agreement by Executive or (ii) regarding the Company’s business or industry properly acquired by Executive in the course of Executive’s career as an Executive in the Company’s industry and independent of Executive’s employment by the Company. For this purpose, information known or available generally within the trade or industry of the Company or any Subsidiary shall be deemed to be known or available to the public.

 

7

 

d.                                      “Subsidiary” shall mean any corporation or other business entity owned or controlled directly or indirectly by CVS Caremark.

 

e.                                       Executive agrees to cooperate with the Company, during the Term and thereafter (including following Executive’s termination of employment for any reason), by being reasonably available to testify on behalf of the Company or any Subsidiary in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any Subsidiary, in any such action, suit, or proceeding, by providing information and meeting and consulting with the Board or its representatives or counsel, or representatives or counsel to the Company, or any Subsidiary as requested; provided, however that the same does not materially interfere with Executive’s then current professional activities. The Company agrees to reimburse Executive on an after tax basis, for all reasonable expenses actually incurred in connection with Executive’s provision of testimony or assistance.

 

f.                                        Executive agrees that, during the Term and thereafter (including following Executive’s termination of employment for any reason) Executive will not make statements or representations, or otherwise communicate, directly or indirectly, in writing, orally, or otherwise, or take any action which may, directly or indirectly, disparage or be damaging to the Company or any Subsidiary or their respective officers, directors, employees, advisors, businesses or reputations. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from making truthful statements or disclosures that are required by applicable law, regulation or legal process.

 

5.                                      Non-solicitation.

 

During the period beginning with the Effective Date and ending 18 months following the termination of Executive’s employment with the Company, Executive, whether acting on Executive’s own behalf or by, through or on behalf of any third party, shall not (a) hire any employees of the Company or any Subsidiary, or recruit or solicit any such employees or encourage them to terminate their employment with the Company or any Subsidiary; (b) accept business from any customers of the Company or any Subsidiary, or solicit or encourage any customers, joint venture partners or investors of the Company or any Subsidiary to terminate or diminish their relationship with the Company or any Subsidiary or to violate any agreement with the Company or any Subsidiary. For purposes of subsection 5(a), an employee of the Company or any Subsidiary means any person who was employed by the Company or any Subsidiary within 180 days of such hiring, recruitment, solicitation or encouragement. Executive agrees to make any employer with whom Executive becomes employed during the 18-month period following Executive’s termination with the Company aware of this non-solicitation obligation upon commencing employment with such subsequent entity.

 

6.                                      Remedies.

 

In addition to whatever other rights and remedies the Company may have at equity or in law, the Company (a) shall have the right to immediately terminate all payments and benefits due under this Agreement if Executive breaches any of the provisions contained in Sections 4 or 5 above, and (b) shall have the right to seek injunctive relief in any court of competent jurisdiction if Executive breaches or threatens to breach any of the provisions contained in Sections 4 or 5 above. Executive acknowledges that such a breach would cause irreparable injury and that money damages would not provide an adequate remedy for the Company; provided, however, the foregoing shall not prevent Executive from contesting the issuance of any such injunction on the ground that no violation or threatened violation of Sections 4 or 5 has occurred.

 

8

 

7.                                      Effect of Agreement on Other Benefits.

 

Except as specifically provided in this Agreement, the existence of this Agreement shall not be interpreted to preclude, prohibit or restrict the Executive’s participation in any other employee benefit or other plans or programs in which he /she currently participates.

 

8.                                      Not an Employment Agreement.

 

This Agreement is not, and nothing herein shall be deemed to create, a contract of employment between Executive and the Company. The Company may terminate the employment of Executive at any time and for any reason, subject to the terms of any employment agreement between the Company and Executive that may then be in effect.

 

9.                                      Resolution of Disputes.

 

Any controversy or claim arising out of or relating to this Agreement or any breach or asserted breach hereof or questioning the validity and binding effect hereof arising under or in connection with this Agreement, other than seeking injunctive relief under Sections 4 or 5, shall be resolved by binding arbitration, to be held at an office closest to the Company’s principal offices in accordance with the rules and procedures of the American Arbitration Association.  Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.  Pending the resolution of any arbitration or court proceeding, the company shall continue payment of all amounts and benefits due Executive under this Agreement.  All reasonable costs and expenses of any arbitration or court proceeding (including fees and disbursements of counsel) shall be paid on behalf of or reimbursed to Executive promptly by the Company; provided, however, that no reimbursement shall be made of such expenses if and to the extent the arbitrator(s) determine(s) that any of Executive’s litigation assertions or defenses were in bad faith or frivolous.

 

10.                               Assignability; Binding Nature.

 

This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of Executive) and permitted assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred in connection with the sale or transfer of all or substantially all of the assets of the Company, provided that the assignee or transferee is the successor to all or substantially all of the assets of the Company and such assignee or transferee assumes the liabilities, obligations and duties of the Company, as contained in this agreement, either contractually or as a matter of law. The Company further agrees that, in the event of a sale or transfer of assets as described in the preceding sentence, it shall take whatever action it legally can in order to cause such assignee or transferee to expressly assume the liabilities, obligations and duties of the Company hereunder. No rights or obligations of Executive under this Agreement may be assigned or transferred by Executive other than Executive’s, rights to compensation and benefits, which may be transferred only by will or operation of law, except as provided in Section 15 below.

 

11.                               Representation.

 

The Company represents and warrants that it is fully authorized and empowered to enter into this Agreement and that the performance of its obligations under this Agreement will not violate any agreement between it and any other person, firm or organization.

 

12.                               Amendment or Waiver; Section 409A.

 

(a)                                 No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by Executive and an authorized officer of the Company. No waiver by

 

9

 

either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by Executive or an authorized officer of the Company, as the case may be.

 

(b)                                 Executive and Company agree that it is the intent of the parties that this Agreement not violate any applicable provision of, or result in any additional tax or penalty under, Section 409A of the Code, as amended, and that to the extent any provisions of this Agreement do not comply with such Code Section 409A the parties will make such changes as are mutually agreed upon in order to comply with Code Section 409A.  In all events, to the extent required to avoid a violation of the applicable rules under all Section 409A by reason of Code Section 409A(a)(2)(B)(i), payment of any amounts subject to Code Section 409A shall be delayed until the relevant date of payment that will result in compliance with the rules of Code Section 409A(a)(2)(B)(i).

 

13.                               Severability.

 

In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.

 

14.                               Survivorship.

 

The respective rights and obligations of the Parties hereunder shall survive any termination of Executive’s employment to the extent necessary to the intended preservation of such rights and obligations.

 

15.                               Beneficiaries/References.

 

Executive shall be entitled, to the extent permitted under any applicable law, to select and change a beneficiary or beneficiaries to receive any compensation or benefit payable hereunder following Executive’s death by giving the Company written notice thereof. In the event of Executive’s death or a judicial determination of Executive’s incompetence, references in this Agreement to Executive shall be deemed, where appropriate, to refer to Executive’s beneficiary, estate or other legal representative.

 

16.                               Governing Law/Jurisdiction.

 

This Agreement shall be governed by and construed and interpreted in accordance with the laws of Rhode Island without reference to principles of conflict of laws. Subject to Section 6, the Company and Executive hereby consent to the jurisdiction of any or all of the following courts for purposes of resolving any dispute under this Agreement: (i) the United States District Court for Rhode Island or (ii) any of the courts of the State of Rhode Island. The Company and Executive further agree that any service of process or notice requirements in such proceeding shall be satisfied if the rules of such court relating thereto have been substantially satisfied. The Company and Executive hereby waive, to the fullest extent permitted by applicable law, any objection which it or he/she may now or hereafter have to such jurisdiction and any defense of inconvenient forum.

 

17.                               Notices.

 

Any notice given to a Party shall be in writing and shall be deemed to have been given when delivered personally or sent by certified or registered mail, postage prepaid, return receipt requested, duly addressed to the Party concerned at the address indicated below or to, such changed address as such Party may subsequently give such notice of:

 

10

 

If to CVS:

 

CVS Pharmacy, Inc.
 One CVS Drive
 Woonsocket, RI 02895
 Attention: Corporate Secretary

 

If to Executive:

 

Mark Cosby
 78 Doubling Road
 Greenwich, CT 06830

 

18.                               Headings.

 

The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.

 

19.                               Counterparts.

 

This Agreement may be executed in two or more counterparts.

 

11

 

In WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written above.

 

	
 
    	
CVS   Pharmacy, Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
  /s/ Lisa Bisaccia
    
	
 
    	
 
    	
Lisa Bisaccia
    
	
 
    	
 
    	
SVP and Chief   Human Resources Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
Executive
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Mark Cosby
    
	
 
    	
Mark Cosby
    
	
 
    	
EVP, CVS Caremark   and President, CVS/pharmacy
    

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]